Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

March 24, 2017

Dr. Berenson stated, "The consequences of bone loss in cancer patients due to increased bone resorption can be devastating, including fractures, bone pain and hypercalcemia. Prior studies indicated that Lyn and Fyn kinases have negative impacts on osteoclasts, thus potentially reducing bone resorption, which prompted us to evaluate bafetinib's osteoclast inhibitory activity in bone deterioration using cells from multiple myeloma patients. We are encouraged by the results."

CytRx President and CEO Steven A. Kriegsman said, "Results from these first-ever studies evaluating bafetinib's anti-bone resorptive effects showed that this kinase inhibitor could present a new therapeutic option to reduce skeletal complications in cancer patients. Reduction of bone loss represents one of multiple oncology indications in which bafetinib could represent an effective treatment."

CytRx is currently evaluating bafetinib in three ongoing clinical trials: the PROACT Phase 2 proof-of-concept prostate cancer clinical trial in patients with advanced cancers; the ENABLE Phase 2 proof-of-concept clinical trial in patients with a late-stage form of leukemia known as high-risk B-cell chronic lymphocytic leukemia; and a pharmacokinetic clinical trial in patients with recurrent brain tumors.

SOURCE CytRx Corporation